文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

机械性神经保护降低经皮左心耳封堵术相关无症状脑梗死风险的随机临床试验依据与设计:LAAC-SBI试验研究方案

Rationale and design of a randomized clinical trial evaluating the efficacy of mechanical neuroprotection in reducing the risk of silent brain infarcts associated with percutaneous left atrial appendage closure: study protocol for a LAAC-SBI trial.
PubMed 文献 · Trials · 2023-11-23

LAAC-SBI试验为前瞻性、多中心、随机、双盲干预研究,计划纳入240例患者,每组120例,评估左心耳封堵术中使用Sentinel CPS对无症状脑梗死及认知与情绪结局的影响。主要终点为弥散加权磁共振成像检测的新发无症状脑梗死或卒中灶数量,观察期2年。

要点

  • LAAC-SBI试验为前瞻性、多中心、随机、双盲干预研究,计划纳入240例患者,每组120例。
  • 主要终点为弥散加权磁共振成像检测的新发无症状脑梗死或卒中灶数量。
  • 次要终点包括认知功能恶化、痴呆综合征发生及抑郁障碍,采用MoCA、TMT、COWAT和HADS评估。

核心结论

  • 若研究显示LAAC中使用脑保护装置可降低无症状脑梗死发生率并改善认知与情绪结局,将对临床管理标准产生重要影响。
  • 这将支持神经保护装置不仅用于LAAC,也可用于房颤消融或经导管二尖瓣介入等存在栓塞事件及后续脑损伤风险的操作。

研究设计与样本

  • LAAC-SBI试验为前瞻性、多中心、随机、双盲干预研究。
  • 计划纳入240例患者,每组120例;研究组在LAAC中使用Sentinel CPS,对照组行LAAC不使用Sentinel CPS。
  • 患者观察期为2年。

主要发现

  • 主要终点为弥散加权磁共振成像检测的新发无症状脑梗死或卒中灶数量。
  • 次要终点包括认知功能恶化、痴呆综合征发生及抑郁障碍,采用MoCA、TMT、COWAT和HADS等问卷工具评估。

关键数值与推荐

  • 研究组在LAAC中使用Sentinel CPS,对照组行LAAC不使用Sentinel CPS。
  • 主要终点为弥散加权磁共振成像检测的新发无症状脑梗死或卒中灶数量。
  • 次要终点包括认知功能恶化、痴呆综合征发生及抑郁障碍,采用MoCA、TMT、COWAT和HADS评估。
  • 患者观察期为2年。
  • 试验注册号ClinicalTrials.gov NCT05369195,注册日期2022年5月11日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left atrial appendage closure (LAAC) procedures prevent cardioembolic stroke in patients with atrial fibrillation who have contraindications to oral anticoagulant medications. However, these procedures carry certain risks of peri-procedural complications. One such complication is silent brain infarcts (SBI), which can lead to cognitive impairment and mood disturbances. The implementation of mechanical neuroprotection systems during LAAC procedures may reduce the risk of SBI and associated cognitive and mood disorders. METHODS: The LAAC-SBI trial is a prospective, multicenter, randomized, and double-blind interventional study. The study aims to enroll a total of 240 patients, with 120 patients allocated to each group. The study group will evaluate the use of the Sentinel CPS during LAAC, while the control group will undergo LAAC procedures without the Sentinel CPS. The primary endpoint of the study is the number of new SBIs or stroke foci detected by diffusion-weighted magnetic resonance imaging (DW MRI). Secondary endpoints include deterioration of cognitive function, development of dementia syndrome, and occurrence of depressive disorders. These endpoints will be assessed using questionnaire tools such as the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), Controlled Oral Word Association Test (COWAT), and Hospital Anxiety and Depression Scale (HADS). The observational period for patients in the study is 2 years. DISCUSSION: If the study demonstrates a favorable outcome with reduced incidence of SBI and improved cognitive and mood outcomes in patients receiving cerebral protection devices during LAAC, it will have significant implications for clinical management standards. This would support the use of neuroprotection devices not only for LAAC but also in procedures such as atrial fibrillation ablation or transcatheter mitral valve interventions, where the risk of embolic events and subsequent brain injury may also be present. TRIAL REGISTRATION: ClinicalTrials.gov NCT05369195. Registration on 11.05.2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Streb W, Lasek-Bal A, Mitręga K, et al. Rationale and design of a randomized clinical trial evaluating the efficacy of mechanical neuroprotection in reducing the risk of silent brain infarcts associated with percutaneous left atrial appendage closure: study protocol for a LAAC-SBI trial. Trials. 2023. PMID: 37996955. doi:10.1186/s13063-023-07766-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。